- Home
- PGP vs ATRA Comparison
PGP vs ATRA Comparison
Compare PGP & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGP | ATRA |
|---|---|---|
| Founded | 2003 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 98.0M | 94.2M |
| IPO Year | 2005 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PGP | ATRA |
|---|---|---|
| Price | $8.44 | $9.49 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 54.3K | 42.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | ★ 122.52 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $120,772,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.04 | $3.92 |
| 52 Week High | $9.41 | $19.15 |
Technical Indicators
Market Signals| Indicator | PGP | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 50.57 |
| Support Level | $8.33 | $8.98 |
| Resistance Level | $8.91 | $10.02 |
| Average True Range (ATR) | 0.12 | 0.70 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 24.18 | 26.09 |
Price Performance
Historical ComparisonAbout PGP Pimco Global StocksPlus & Income Fund of Beneficial Interest
PIMCO Global Stocksplus & Income Fund is a closed-end management investment company. The objective of the fund is to seek a total return comprised of current income, current gains, as well as long-term capital appreciation. The fund invests a majority of the fund's net assets in a combination of securities and instruments that provide exposure to stocks and or produce income.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.